相关临床试验
4
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
25.0%
终止
1
25.0%
Unknown
2
50.0%
暂无批准数据
- XTL Biopharmaceuticals announced acquisition of Psyga Bio for 40% equity stake, positioning the company as a leading psychedelic biotechnology platform with seven approved Phase 2a clinical trials. - The transaction follows President Trump's April 18, 2026 Executive Order directing FDA to accelerate psychedelic therapy research and approval pathways for serious mental illness treatment. - Psyga operates a licensed GMP-ready manufacturing facility for psilocybin and ibogaine production, with a proprietary library of over 180 unique mushroom strains. - The deal includes milestone-based earnouts totaling 30% additional equity tied to clinical trial commencement, target achievement, and ibogaine commercialization partnerships.
- XTL Biopharmaceuticals announced a binding agreement to acquire 85% of NeuroNOS Ltd., a biotechnology company developing disease-modifying therapeutics for Autism Spectrum Disorder and neuro-oncology. - The acquisition positions XTL as a major player in the autism therapeutics market, addressing a critical unmet need affecting 1 in 31 U.S. children with no FDA-approved disease-modifying therapies currently available. - NeuroNOS has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma, with its platform targeting nitric oxide dysregulation in the brain rather than just managing symptoms. - Beyond Air will receive 19.9% of XTL's shares, $1 million in cash, and up to $32.5 million in milestone payments, while NeuroNOS becomes XTL's flagship platform for autism and neuro-oncology therapeutics.
